The National Institute for Health and Care Excellence (NICE) are carrying out a consultation on the draft guideline on smoking cessation interventions and services delivered in primary care and community settings. Feedback and comments are invited on the draft guideline and accompanying documentation. The consultation closes on 1 November 2017.
The latest newsletter from the National Institute for Health and Care Excellence (NICE) carries feature articles on managing sepsis and on the recommendation that people at the highest risk of type 2 diabetes should be offered lifestyle tips. There is also news of NICE advice on ear infections, ADHD diagnosis, endometriosis and on the use of dipstick urine tests for suspected urinary tract infections in children. NICE have also announced a review of the guideline on chronic fatigue syndrome and that lung cancer patients in England can be prescribed the drug nivolumab.
The National Institute for Health and Care Excellence (NICE) have published their August newsletter. It contains details of their recently published annual report and news features on GPs calling for a national autism register and Cancer Drug Fund approvals. There is also news of recent NICE guidance on bisphosphonates, statins in kidney disease patients, a pancreatic cancer drug (nab-paclitaxel) and when to give antibiotics for common infections. The chair of NICE has a short blog post on the priniciples that guide NICE decisions.
A blog post from the Office of Health Economics summarises the current situation on the use of the EQ-5D-5L value set, highlights the recent NICE decision and explains and discusses the differences between the EQ-5D-5L and the EQ-5D-3L. It also discusses future research and policy positions.
The published research paper is also available and is discussed in the Academic Health Economists’ Blog.
Devlin NJ, Shah KK, Feng Y, Mulhern B, van Hout B. Valuing health-related quality of life: An EQ-5D-5L value set for England. Health Economics. 2017;1–16.
The National Institute for Health and Care Excellence (NICE) have issued a position statement on the use of the EQ-5D-5L valuation set. The statement recommends not using the 5L valuation set for evidence submissions to NICE that use cost-utility analyses. Preference should be given to the EQ-5D-3L valuation set. The full statement gives more detail on the decision from the NICE Decision Support Unit.
The National Institute for Health and Care Excellence (NICE) have published guidance on Collagenase clostridium histolyticum for treating Dupuytren’s contracture [TA459]. The treatment is recommended only under specific circumstances while an on-going trial is conducted. HERU staff contributed to the evidence for the development of the guidance.
The Decision Support Unit (DSU) at the National Institute for Health and Care Excellence (NICE) have produced a Technical Support Document on the use of partitioned survival analysis as a decision modelling tool in health technology assessments. The report contains a description of partitioned survival analysis and how if differs from other models, a review of it’s use in recent NICE Technology Appraisals of cancer treatments, a critique of the model and a series of recommendations.
The DSU is a collaboration between the Universities of Sheffield, York and Leicester that is commissioned by NICE to provide a research and training resource to support the Institute’s Technology Appraisal Programme.
Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU Technical Support Document 19. Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review. 2017 [Available from http://www.nicedsu.org.uk%5D